REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
13.95
-1.70 (-10.86%)
Jul 10, 2026, 4:00 PM EDT - Market closed
REGENXBIO Employees
REGENXBIO had 371 employees as of December 31, 2025. The number of employees increased by 18 or 5.10% compared to the previous year.
Employees
371
Change (1Y)
18
Growth (1Y)
5.10%
Revenue / Employee
$236,717
Profits / Employee
-$781,704
Market Cap
721.20M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 371 | 18 | 5.10% |
| Dec 31, 2024 | 353 | 9 | 2.62% |
| Dec 31, 2023 | 344 | -57 | -14.21% |
| Dec 31, 2022 | 401 | 29 | 7.80% |
| Dec 31, 2021 | 372 | 66 | 21.57% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Gyre Therapeutics | 625 |
| Omeros | 175 |
| Allogene Therapeutics | 152 |
| Prime Medicine | 146 |
| Aura Biosciences | 113 |
| SpyGlass Pharma | 68 |
| Candel Therapeutics | 55 |
| Bright Minds Biosciences | 26 |
RGNX News
- 13 days ago - Regenxbio says first patient dosed in Phase IIb/III NAAVIGATE trial - TheFly
- 13 days ago - REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone - PRNewsWire
- 18 days ago - Regenxbio completes dosing in confirmatory study of RGX-202 - TheFly
- 18 days ago - REGENXBIO Completes Dosing in Confirmatory Study of RGX-202, Marking Completion of Registrational Development Program and Supporting Planned BLA Submission in Q3 2026 - PRNewsWire
- 19 days ago - Regenxbio price target raised to $32 from $27 at Baird - TheFly
- 20 days ago - H.C. Wainwright notes Regenxbio doesn’t need more studies for BLA resubmission - TheFly
- 20 days ago - Regenxbio aligns with FDA on path forward for Navsunli - TheFly
- 20 days ago - REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI™ BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS II - PRNewsWire